The Andalusian Health Service (SAS) has called a framework agreement for the selection of suppliers of biosimilar medicines to be used in SAS health centers for a value of 218 million euros per year.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
